Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile

European Journal of Pharmacology
A W SchmidtS H Zorn

Abstract

Ziprasidone is a novel antipsychotic agent with a unique combination of pharmacological activities at human receptors. Ziprasidone has high affinity for human 5-HT receptors and for human dopamine D(2) receptors. Ziprasidone is a 5-HT(1A) receptor agonist and an antagonist at 5-HT(2A), 5-HT(2C) and 5-HT(1B/1D) receptors. Additionally, ziprasidone inhibits neuronal uptake of 5-HT and norepinephrine comparable to the antidepressant imipramine. This unique pharmacological profile of ziprasidone may be related to its clinical effectiveness as a treatment for the positive, negative and affective symptoms of schizophrenia with a low propensity for extrapyramidal side effects, cognitive deficits and weight gain.

References

Oct 6, 1998·European Journal of Pharmacology·A Newman-TancrediMark J Millan
Apr 8, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David G DanielM Lakshminarayanan
Oct 12, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J S SprouseS H Zorn

Citations

Dec 6, 2005·Psychopharmacology·C A JenningsE Southam
Apr 7, 2005·European Archives of Psychiatry and Clinical Neuroscience·Hans-Jürgen Möller
Jul 5, 2005·European Archives of Psychiatry and Clinical Neuroscience·Hans-Jürgen Möller
Mar 7, 2012·Journal of Neural Transmission·Akira OtaMiyuki Ota
Nov 5, 2008·Current Psychiatry Reports·G I Papakostas, Richard C Shelton
Jan 25, 2012·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Dustin M Hipp, E Wesley Ely
Dec 27, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Dennis H KimStephen M Stahl
May 11, 2007·Journal of Child and Adolescent Psychopharmacology·Harpreet S Duggal
Jul 15, 2004·Clinical Neuropharmacology·Sol JaworowskiHarry Hirsch
Apr 23, 2004·International Clinical Psychopharmacology·David G DanielEdmund P Harrigan
Apr 23, 2004·International Clinical Psychopharmacology·M Nishida, M Nakamura
Mar 30, 2005·Clinical Neuropharmacology·Vladimir LernerChanoch Miodownik
May 27, 2010·Clinical Neuropharmacology·Sung-Wan KimJin-Sang Yoon
Jul 7, 2010·Psychiatry and Clinical Neurosciences·Pei-Yin LinShih-Jen Tsai
Sep 16, 2005·Cephalalgia : an International Journal of Headache·C M CahillK C Murphy
Sep 12, 2008·Human & Experimental Toxicology·Kennon HeardN R Zahniser
Jan 26, 2013·Annals of General Psychiatry·David M GardnerRichard Williams
Jun 20, 2007·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·Nathan R ClevelandKennon Heard
Jun 1, 2006·Neuropsychiatric Disease and Treatment·Emanuela MundoAlfredo Carlo Altamura
Oct 20, 2005·Clinical Pharmacokinetics·Sheldon H Preskorn
Jun 2, 2009·CNS Drugs·Julian N TrollorPerminder S Sachdev
Jan 22, 2010·CNS Drugs·Richard C SheltonSara A Corya
Jul 10, 2014·ISRN Psychiatry·Natalia BartolommeiLorenzo Lattanzi
Apr 28, 2005·Expert Review of Neurotherapeutics·Christos BallasClaudia Baldassano
Aug 9, 2006·Expert Review of Neurotherapeutics·Nick C Patel, Paul E Keck
Aug 1, 2013·Expert Review of Neurotherapeutics·Changsu HanChi-Un Pae
Nov 26, 2011·Expert Review of Clinical Pharmacology·Emilio SacchettiPaolo Valsecchi
Nov 6, 2007·Expert Opinion on Emerging Drugs·Nirvana S Pillay, Dan J Stein
May 31, 2006·Expert Opinion on Pharmacotherapy·Marcio Versiani
Jul 28, 2010·Expert Opinion on Pharmacotherapy·Andrea FagioliniAlessandro Rossi
Jul 2, 2009·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Kennon HeardShay Krier
Sep 22, 2005·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiWFSBP Task Force on Treatment Guidelines for Schizophrenia
Jan 8, 2016·Progress in Neuro-psychopharmacology & Biological Psychiatry·A ChagraouiM Bourin
Jan 3, 2012·Metabolism: Clinical and Experimental·Subin ParkJin Pyo Hong
Jan 27, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Yasushi SatoSunao Kaneko
Nov 26, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Yi-Wei YehChih-Lun Chen
Sep 9, 2008·European Journal of Pharmacology·Zahra NourianTorsten Kristensen
Mar 21, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Daniela F FukushiroR Frussa-Filho
May 20, 2005·Journal of Clinical Pharmacology·Jeffrey J MiceliThomas G Tensfeldt
Dec 2, 2008·CNS Neuroscience & Therapeutics·Adriane R RosaEduard Vieta
Jan 15, 2008·Acta Psychiatrica Scandinavica·Richard C Shelton, G I Papakostas
Jul 14, 2007·CNS Drug Reviews·William M Greenberg, Leslie Citrome
Jan 30, 2014·Clinical and Experimental Pharmacology & Physiology·A W HollaisR Frussa-Filho
Nov 24, 2004·European Journal of Pharmacology·Shona L KirkG P Reynolds
Dec 21, 2004·Journal of the American Academy of Child and Adolescent Psychiatry·Jennifer BlairAndrés Martin
Oct 7, 2004·European Journal of Pharmacology·Vera BubeníkováCyril Höschl
Aug 25, 2006·Schizophrenia Research·Marci L ChewGeorges Gharabawi
Apr 4, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mehmet YumruEsen Savas
Jan 31, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Panayiota G Michalopoulou, Lefteris Lykouras
Oct 29, 2005·Pharmacology, Biochemistry, and Behavior·Richard YoungRichard A Glennon
Oct 10, 2014·Psychiatry and Clinical Neurosciences·Ichiro KusumiYoshito Takahashi
May 26, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Kyung-Yoon KamSung Goo Kang
Dec 9, 2014·Expert Opinion on Drug Metabolism & Toxicology·Roberto MandrioliLaura Mercolini
May 9, 2012·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·R Scott ObachAmin M Kamel
Jun 15, 2010·Drug and Alcohol Dependence·Katsutoshi ShiodaSatoshi Kato
Aug 30, 2012·Neurochemistry International·Osamu IchikawaKazuto Yamazaki
May 24, 2011·Journal of Affective Disorders·Konstantinos N FountoulakisHagop Akiskal
Dec 19, 2013·The International Journal of Neuropsychopharmacology·Eduardo A V MarinhoR Frussa-Filho
Jun 28, 2005·International Journal of Psychiatry in Medicine·Steven A ColeAngela Smith
Jun 30, 2016·Progress in Neuro-psychopharmacology & Biological Psychiatry·Deniz Sezlev-BilecenTulin Yanik
Apr 6, 1999·Schizophrenia Research·D E Casey
Oct 30, 2016·Progress in Neuro-psychopharmacology & Biological Psychiatry·A J Oliveira-LimaR Frussa-Filho
Dec 5, 2003·Journal of Geriatric Psychiatry and Neurology·Jacobo Mintzer, Steven D Targum
Jan 17, 2017·Expert Review of Neurotherapeutics·Ricardo P GarayPierre-Michel Llorca
Oct 14, 2003·Bioorganic & Medicinal Chemistry Letters·Donald M N SikazweSeth Y Ablordeppey
Oct 10, 2007·Harvard Review of Psychiatry·W Gordon Frankle
Apr 21, 2007·Journal of Psychopharmacology·Cengiz AkkayaSelcuk Kirli
Feb 25, 2005·Journal of Psychopharmacology·Lawrence ScahillAndrés Martin
Oct 10, 2018·Journal of Clinical Psychopharmacology·Michael Poyurovsky, Abraham Weizman
Oct 1, 2003·Expert Review of Pharmacoeconomics & Outcomes Research·Prakash S Masand, Sanjay Gupta
May 1, 2002·Expert Review of Neurotherapeutics·Rosaria Di Lorenzo, Susanna Genedani
Sep 18, 2007·Journal of Clinical Psychopharmacology·Albert K K Chung, Siew-eng Chua
Mar 30, 2005·Therapeutic Drug Monitoring·Julia SachseChristoph Hiemke
Nov 18, 2008·Journal of Clinical Psychopharmacology·Young-Min ParkSeung-Gul Kang
Jun 4, 2010·Journal of Clinical Psychopharmacology·Alexander C Tsai
Apr 14, 2010·The Journal of ECT·Vasilios G MasdrakisPanagiotis Oulis
Jul 16, 2010·Journal of Clinical Psychopharmacology·Christina L Rim, Michael J Gitlin
Feb 27, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·R Alexander BantickPaul M Grasby
Nov 24, 2004·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Paz TorenAbraham Weizman
Mar 17, 2007·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Murat Eren OzenHasan Herken
Jul 5, 2011·Expert Review of Neurotherapeutics·Maurizio PompiliPaolo Girardi
May 17, 2006·The Journal of Pharmacology and Experimental Therapeutics·Alvin V TerrySahebarao P Mahadik
Nov 13, 2017·Pharmacological Reports : PR·Hong-Yan GouJin Li
May 24, 2013·American Journal of Therapeutics·Samir Kumar PraharajVinod Kumar Sinha
Mar 18, 2003·Journal of Clinical Psychopharmacology·Neil S Kaye
Jun 27, 2003·Journal of Clinical Psychopharmacology·Christine BeedhamR Scott Obach
Jun 30, 2015·Journal of Clinical Psychopharmacology·Jonathan F ListerJennifer R Bean
Aug 22, 2020·The International Journal of Neuropsychopharmacology·Tsuyoshi OkadaShiro Suda
May 7, 2020·Frontiers in Endocrinology·Samantha Alvarez-HerreraLenin Pavón
Oct 12, 2004·CNS Spectrums·Herbert Y Meltzer
Oct 12, 2004·CNS Spectrums·Darius K Shayegan, Stephen M Stahl
Sep 18, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Kazuki TeradaYoshiharu Karube
Dec 31, 2005·CNS Spectrums·Charles B NemeroffDavid G Daniel
Jan 1, 2015·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·N M Zalutskaya
Oct 22, 2005·Clinical Neuropharmacology·Marc ZiegenbeinHeike E Kuenzel
Aug 14, 2018·Medicinal Chemistry Research : an International Journal for Rapid Communications on Design and Mechanisms of Action of Biologically Active Agents·Jacek StefanowiczJadwiga Turło
Feb 24, 2004·CNS Spectrums·Carol A Tamminga
Jun 20, 2018·Clinical Pharmacokinetics·Massimo Carlo MauriAlfredo Carlo Altamura
Mar 30, 2005·Clinical Neuropharmacology·Anne M KeatingCharles E Dean
Dec 20, 2016·Journal of Child and Adolescent Psychopharmacology·Lauren T SchumacherJames G MacKenzie
Nov 28, 2020·Current Treatment Options in Oncology·Mellar P Davis, Gareth J Sanger

Related Concepts

Ziprasidone hydrochloride, monohydrate
Quetiapine
Metazoa
Benzodiazepines
Leponex
Dibenzothiazepines
Haldol
Neurons
Norepinephrine, (+, -)-Isomer
Piperazines

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Related Papers

Expert Opinion on Investigational Drugs
David G Daniel, L F Copeland
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine
Nathan R ClevelandKennon Heard
© 2021 Meta ULC. All rights reserved